

# ● PRINTER RUSH ●

(PTO ASSISTANCE)

Application: <u>10/694614</u>	Examiner: <u>Smith</u>	GAU: <u>1645</u>
From: <u>T. McGill</u>	Location: <u>IDC</u> FMF FDC	Date: <u>5-4-05</u>
Tracking #: <u>6088066</u>		Week Date: <u>3-21-05</u>

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input type="checkbox"/> Other
<input type="checkbox"/> DRW	_____	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input checked="" type="checkbox"/> SPEC	<u>10-27-03</u>	

[RUSH] MESSAGE: Attn: Chief Draftsperson

The specification does not contain a  
paragraph referring to colored drawings  
as required per 37 CFR 1.84(a)(2)(iii).  
Thank you

[XRUSH] RESPONSE: (SEE ATTACHMENT)  
ATTACHED IS THE PARAGRAPH IN WHICH  
IS TO BE INSERTED IN THE ~~THE~~ SPECIFICATION

INITIALS: JOC

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.  
 REV 10/04

- a) providing a vaccine comprised of the protein encoded by the construct of Figure 1; and
- b) treating a mammal in need thereof with an effective anti-*Y. pestis* amount of the vaccine.

### Brief Description Of The Drawings

5  
SEE  
ATTACHMENT

FIGURE 1A is a scheme of construction of a recombinant plasmid formed by joining the DNA encoding the signal sequence and IgG binding domains of staphylococcal protein A and that of all but the 201 N-terminal base pairs of *Y. pestis* V antigen; antibody to which is capable of effecting immunological treatment against *Y. pestis*;

FIGURE 1B cites a restriction endonuclease attack on the V antigen;

FIGURE 2 is a silver-stained extended SDS gel of whole cells of *E. coli* BL 21 containing the vector plasmid pKK223-3 (lane 1) or recombinant plasmid pKVE14 (lane 2);

FIGURE 3 are immunoblots prepared with rabbit polyclonal anti V antigen (A) mouse monoclonal anti V antigen 15A4.8 (B) and mouse monoclonal anti V antigen 3A4.1 (C) directed against whole cells of *E. coli* containing the vector plasmid pKK223-3 (lane 1) or recombinant plasmid pKE14 (lane 2);

FIGURE 4 are immunoblots prepared with rabbit anti-native V antigen purified from *Y. pestis* KIM (A), anti-recombinant V antigen (B), anti-protein A-V antigen fusion protein (C), and anti-Protein A (D) directed

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.